Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA
The recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of the suitable health measures raised the importance of available, rapid, and accurate diagnostic approaches. The purpose of this study is to d...
Saved in:
Published in | Human antibodies Vol. 30; no. 2; p. 105 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
2022
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of the suitable health measures raised the importance of available, rapid, and accurate diagnostic approaches.
The purpose of this study is to describe a rapid in-house optimized ELISA based on the expression of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in a prokaryotic system.
We show the expression of the 30 kDa recombinant SARS-CoV-2 RBD-6×His in four different E. coli strains (at 28∘C using 0.25mM IPTG) including the expression strain E. coli BL21 (DE3) Rosetta Gami. SARS-CoV-2 rRBD-6×His protein was purified, refolded, and used as an antigen coat to assess antibody response in human sera against SARS-CoV-2 infection.
The assessment was carried out using a total of 155 human sero-positive and negative SARS-CoV-2 antibodies. The ELISA showed 69.5% sensitivity, 88% specificity, 78.5% agreement, a positive predictive value (PPV) of 92.3%, and a negative predictive value of 56.5%. Moreover, the optical density (OD) values of positive samples significantly correlated with the commercial kit titers.
Specific human antibodies against SARS-CoV-2 spike protein were detected by rapid in-house ELISA in sera of human COVID-19-infected patients. The availability of this in-house ELISA protocol would be valuable for various diagnostic and epidemiological applications, particularly in developing countries. Future studies are planned for the use of the generated SARS-CoV-2 rRBD-6×His protein in vaccine development and other diagnostic applications. |
---|---|
AbstractList | The recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of the suitable health measures raised the importance of available, rapid, and accurate diagnostic approaches.
The purpose of this study is to describe a rapid in-house optimized ELISA based on the expression of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in a prokaryotic system.
We show the expression of the 30 kDa recombinant SARS-CoV-2 RBD-6×His in four different E. coli strains (at 28∘C using 0.25mM IPTG) including the expression strain E. coli BL21 (DE3) Rosetta Gami. SARS-CoV-2 rRBD-6×His protein was purified, refolded, and used as an antigen coat to assess antibody response in human sera against SARS-CoV-2 infection.
The assessment was carried out using a total of 155 human sero-positive and negative SARS-CoV-2 antibodies. The ELISA showed 69.5% sensitivity, 88% specificity, 78.5% agreement, a positive predictive value (PPV) of 92.3%, and a negative predictive value of 56.5%. Moreover, the optical density (OD) values of positive samples significantly correlated with the commercial kit titers.
Specific human antibodies against SARS-CoV-2 spike protein were detected by rapid in-house ELISA in sera of human COVID-19-infected patients. The availability of this in-house ELISA protocol would be valuable for various diagnostic and epidemiological applications, particularly in developing countries. Future studies are planned for the use of the generated SARS-CoV-2 rRBD-6×His protein in vaccine development and other diagnostic applications. |
Author | El-Shershaby, Asmaa Shaheen, Mohamed N F Hussein, Nahla A El-Hakim, Amr E Shahein, Yasser E Ali, Ibrahim Salamony, Azza Ali, Esraa A A Tabll, Ashraf A Elshall, Mahmoud |
Author_xml | – sequence: 1 givenname: Nahla A surname: Hussein fullname: Hussein, Nahla A organization: Molecular Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, Egypt – sequence: 2 givenname: Esraa A A surname: Ali fullname: Ali, Esraa A A organization: Molecular Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, Egypt – sequence: 3 givenname: Amr E surname: El-Hakim fullname: El-Hakim, Amr E organization: Molecular Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, Egypt – sequence: 4 givenname: Ashraf A surname: Tabll fullname: Tabll, Ashraf A organization: Egypt Center for Research and Regenerative Medicine, Cairo, Egypt – sequence: 5 givenname: Asmaa surname: El-Shershaby fullname: El-Shershaby, Asmaa organization: Molecular Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, Egypt – sequence: 6 givenname: Azza surname: Salamony fullname: Salamony, Azza organization: Egypt Center for Research and Regenerative Medicine, Cairo, Egypt – sequence: 7 givenname: Mohamed N F surname: Shaheen fullname: Shaheen, Mohamed N F organization: Environmental Virology Laboratory, Water Pollution Research Department, Environmental and Climate Change Research Institute, National Research Centre, Dokki, Cairo, Egypt – sequence: 8 givenname: Ibrahim surname: Ali fullname: Ali, Ibrahim organization: Parasitology Department, Theodor Bilharz Research Institute, Giza, Egypt – sequence: 9 givenname: Mahmoud surname: Elshall fullname: Elshall, Mahmoud organization: Parasitology Department, Theodor Bilharz Research Institute, Giza, Egypt – sequence: 10 givenname: Yasser E surname: Shahein fullname: Shahein, Yasser E organization: Molecular Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, Egypt |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35431235$$D View this record in MEDLINE/PubMed |
BookMark | eNqFzruOwjAQQFELLWJ5_QKaH3BBQniUEWIFEtUGITrkxBMYhMeWJyn4eyigprrNKe5A_bBn7Kj-dLnI9HK-OvXUb5rN0mmSZn11y0VQxCE34GuQgBXVVMG1dYbBcEOlt4QC5mKIpYEi_y_02h91AhErDI2PUBJb4gtY714IygdEE8gCsb76VhA2-12Rj1S3NnfB8btDNfnbHNZbHdrSoT2HSM7Ex_kzl3wFT859Q74 |
ContentType | Journal Article |
DBID | NPM |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 1875-869X |
ExternalDocumentID | 35431235 |
Genre | Journal Article |
GroupedDBID | NPM |
ID | FETCH-pubmed_primary_354312352 |
IngestDate | Wed Oct 16 00:41:01 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 2 |
Keywords | COVID-19 SARS-CoV-2 human sera RBD diagnosis ELISA |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-pubmed_primary_354312352 |
PMID | 35431235 |
ParticipantIDs | pubmed_primary_35431235 |
PublicationCentury | 2000 |
PublicationDate | 2022-00-00 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – year: 2022 text: 2022-00-00 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Human antibodies |
PublicationTitleAlternate | Hum Antibodies |
PublicationYear | 2022 |
Score | 3.661273 |
Snippet | The recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 105 |
Title | Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35431235 |
Volume | 30 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3NS8MwFMDDpiC7iOL3x8jBW4nMdv3YsYxKFTfETdltpm3qKttauu6gf70vSbuW4WB6CeWlDSG_NLz3kveC0I3V0kPfpJR0dKqTtqkZxDN0fh9xYHp6EFgB4w79Xt9wX9uPI31Uq71XTi0tM-_W__41ruQ_VEEGXHmU7B_IrhoFATwDXyiBMJRbMbZXaTW5zseDJvnBn_zePRiyyIv5IUGFfoD9v8iUgf0yIN34jagKLHQsyfhRzUjGtQTxDF7i2mhKk4hnZCKTeLlgivP0MLCrOqy71nw5M6A7MiVBn06mtHST2jIG21mkFKSl3JkSFzRYMSXtWVpGRQypJ7dD7MUkpWH-Re6cUNWKc4LJBRXsIWIZ4rrc1Yqb78REFcNXLp93IgQ7q6BLZoKdxkP2VW2L2rXs2UVVHdVNi1_t0X_uNdBeIV4zJoRSMTxA-7k1gG2J9hDV2PwIfZZYcRziAisWWHE57jjHikusuMCKc6xYYsXeFxZYcYEVC6zHqHnvDLsukd0bJzL3yLjouHqCdubxnJ0h7Kshoy1T9alhtqkRWKHWstoUdDGVGXrQOUenGxq52FhziRolziu0G8Ifw65B_cq8phjDH5g2OW0 |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+specific+human+antibodies+against+SARS-CoV-2+receptor+binding+domain+by+rapid+in-house+ELISA&rft.jtitle=Human+antibodies&rft.au=Hussein%2C+Nahla+A&rft.au=Ali%2C+Esraa+A+A&rft.au=El-Hakim%2C+Amr+E&rft.au=Tabll%2C+Ashraf+A&rft.date=2022-01-01&rft.eissn=1875-869X&rft.volume=30&rft.issue=2&rft.spage=105&rft_id=info%3Apmid%2F35431235&rft_id=info%3Apmid%2F35431235&rft.externalDocID=35431235 |